The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Sorafenib in Advanced Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. CONCLUSIONS: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In previously untreated patients with advanced hepatocellular carcinoma, the approved multikinase inhibitors lenvatinib and sorafenib have provided modest median overall survival benefits of 13•6 months (lenvatinib) and 12•3 months (sorafenib).5,6”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Multikinase inhibitors, including sorafenib and lenvatinib, are first-line treatment options for patients with unresectable hepatocellular carcinoma; however, they provide modest improvements in median overall survival (ranging from 12 months to 14 months), along with unsatisfactory safety outcomes.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past two decades, the development of effective systemic therapies has substantially improved the outcomes of patients with advanced-stage HCC2–6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The only FDA-approved drug for advanced HCC, sorafenib is well tolerated in cirrhotic patients (2) and inhibits several tyrosine kinases (e.g. VEGF, PDGFR, ERK/AKT, Ras, etc.), and their downstream oncogenic pathways (35).”
From Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib (2012) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of note, sorafenib performed exceptionally well in patients with non-viral HCCs, with a median OS reaching 18.1 months, considerably longer than that in the SHARP trial (10.7 months) or other sorafenib arms in recent phase three trials (13–15 months), which possibly cause the lack of comparative benefits for atezolizumab-bevacizumab in this subgroup despite preserved absolute benefits [27, 32, 33]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Self-citationClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R. A., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,063
Self-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Thomas MB, 2007, J Clin Oncol, 25, 214s
- Zhu AX, 2007, J Clin Oncol, 25, 231s
Cited by
Sorted by citations
Items 301–400 of 1,040
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
Pinter, M., Jain, R. K., & Duda, D. G. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 352
Heterogeneity of liver cancer and personalized therapy
Li, L., & Wang, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.018 · Cited by 344
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Méndez‐Blanco, C., Fondevila, F., Palomo, A. G., González‐Gallego, J., & Mauriz, J. L. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0159-1 · Cited by 339
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Wang, Y., Chen, M., Wu, Z., Tong, C., Dai, H., Guo, Y., Liu, Y., Huang, J., Lv, H., Luo, C., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440169 · Cited by 338
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Ikeda, K., Kudo, M., Kawazoe, S., Osaki, Y., Ikeda, M., Okusaka, T., Tamai, T., Suzuki, T., Hisai, T., Hayato, S., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1263-4 · Cited by 338
Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
Chang, Y. W., Jeong, S. W., Jang, J. Y., & Kim, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218165 · Cited by 342
“Sorafenib is the treatment of choice for advanced HCC, and lenvatinib has also been recommended as a first-line systemic treatment after its non-inferiority to sorafenib was demonstrated [40,41].”
BackgroundLiedtke, C., Luedde, T., Sauerbruch, T., Scholten, D., Streetz, K. L., Tacke, F., Tolba, R. H., Trautwein, C., Trebicka, J., & Weiskirchen, R. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-19 · Cited by 346
Lacouture, M. E., Wu, S., Robert, C., Atkins, M. B., Kong, H. H., Guitart, J., Garbe, C., Hauschild, A., Puzanov, I. J., Alexandrescu, D. T., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0131 · Cited by 336
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 335
Cicco, P. D., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 341
Treatment of Hepatocellular Carcinoma: A Systematic Review
Lin, S., Hoffmann, K., & Schemmer, P. (2012) · Liver Cancer · doi:10.1159/000343828 · Cited by 337
Yin, L., Li, H., Li, A., Lau, W. Y., Pan, Z., Lai, E. C. H., Wu, M., & Zhou, W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.012 · Cited by 334
Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., Kaseb, A. O., Glover, K. Y., Davila, M. L., & Abbruzzese, J. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3301 · Cited by 334
Shariff, M. I. F., Cox, I. J., Gomaa, A. I., Khan, S. A., Gedroyc, W., & Taylor-Robinson, S. D. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.35 · Cited by 328
Molecular therapies for HCC: Looking outside the box
Faivre, S. J., Rimassa, L., & Finn, R. S. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.010 · Cited by 332
Lyu, N., Wang, X., Li, J.-B., Lai, J.-F., Chen, Q.-F., Li, S.-L., Deng, H.-J., He, M., Mu, L.-W., & Zhao, M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01963 · Cited by 329
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression
Yoo, B. K., Emdad, L., Su, Z.-Z., Villanueva, A., Chiang, D. Y., Mukhopadhyay, N. D., Mills, A. S., Waxman, S., Fisher, R. A., Llovet, J. M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36460 · Cited by 324
Self-citationRecent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0718-5 · Cited by 335
Zhang, Q., Lou, Y., Yang, J., Wang, J., Feng, J., Zhao, Y., Wang, L., Huang, X., Fu, Q., Ye, M., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318912 · Cited by 332
A targetable LIFR−NF-κB−LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
Yao, F., Deng, Y., Zhao, Y., Mei, Y., Zhang, Y., Liu, X., Martinez, C., Su, X., Rosato, R. R., Teng, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27452-9 · Cited by 328
Hagel, M., Miduturu, C., Sheets, M. P., Rubin, N. T., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B. L., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 325
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, É., Taı̈eb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 337
Gillmore, R., Stuart, S., Kirkwood, A. A., Hameeduddin, A., Woodward, N., Burroughs, A. K., & Meyer, T. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.007 · Cited by 323
Targeting angiogenesis in oncology, ophthalmology and beyond
Cao, Y., Langer, R., & Ferrara, N. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00671-z · Cited by 339
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan, J. D., Kennedy, E. B., Abou‐Alfa, G. K., Beal, E. W., Finn, R. S., Gade, T. P. F., Goff, L. W., Gupta, S., Guy, J. E., Hoang, H. T., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02745 · Cited by 349
Roessler, S. K., Long, E. L., Budhu, A., Chen, Y., Zhao, X., Ji, J., Walker, R. L., Jia, H., Ye, Q., Qin, L., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.12.039 · Cited by 320
Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review
Desai, A., Sandhu, S., Lai, J., & Sandhu, D. S. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i1.1 · Cited by 328
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V. G., Mehta, N., Parikh, N. D., Abou‐Alfa, G. K., Singal, A. G., & Yang, J. D. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 359
Medical therapies for hepatocellular carcinoma: a critical view of the evidence
Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.199 · Cited by 314
Self-citationNotch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice
Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., Rodríguez‐Carunchio, L., Solé, M., Thung, S. N., Stanger, B. Z., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.002 · Cited by 317
Self-citationChen, K., Chen, H., Tai, W., Feng, W.-C., Hsu, C., Chen, P., & Cheng, A. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175786 · Cited by 317
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma
Li, Z., Dai, H.-Q., Huang, X., Ji, F., Deng, J.-H., Wang, Z.-X., Yang, X., Liu, Y., Wu, Y., Chen, P.-H., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0478-3 · Cited by 322
“7 months [3], while another study conducted in HBVdominant Asian HCC patients also revealed an elongation of median overall survival from 4.”
BackgroundMcCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 317
Radioembolization for hepatocellular carcinoma
Sangro, B., Iñarrairaegui, M., & Bilbao, J. I. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.012 · Cited by 314
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.031 · Cited by 314
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 324
Kudo, M., Han, K., Ye, S.-L., Zhou, J., Huang, Y., Lin, S.-M., Wang, C.-K., Ikeda, M., Chan, S. L., Choo, S. P., et al. (2020) · Liver Cancer · doi:10.1159/000507370 · Cited by 314
Ren, X., Li, Y., Zhou, Y., Hu, W., Yang, C., Jing, Q., Zhou, C., Wang, X., Hu, J., Wang, L., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102122 · Cited by 315
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1170 · Cited by 312
Population-based risk factors and resource utilization for HCC: US perspective
Sanyal, A. J., Poklepovic, A. S., Moyneur, É., & Barghout, V. E. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.506375 · Cited by 312
Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment
Vilchez, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.823 · Cited by 314
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 318
“TKIs that mainly (but not exclusively) target angiogenesis are the standard of care but offer limited survival benefit.(25,26) In recent years, immune-based therapies, such as ICIs, have emerged as novel pillars of cancer therapy (Fig.”
BackgroundSelf-citationMolecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
Hoshida, Y., Toffanin, S., Lachenmayer, A., Villanueva, A., Mínguez, B., & Llovet, J. M. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247131 · Cited by 317
Self-citationSorafenib: A Review in Hepatocellular Carcinoma
Keating, G. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0484-7 · Cited by 310
UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma
Mudbhary, R., Hoshida, Y., Chernyavskaya, Y., Jacob, V., Villanueva, A., Fiel, M. I., Chen, X., Kojima, K., Thung, S. N., Bronson, R. T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.003 · Cited by 310
Self-citationTumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 336
“Since the first tyrosine kinase inhibitor (TKI) sorafenib was proven to extend the survival in advanced HCC patients without compromising liver function in 2008 (5), multi-TKIs and vascular endothelial growth factor (VEGF) inhibitors have been integrated into standard systemic therapy for advanced HCC (6–9).”
BackgroundEpithelial–Mesenchymal Transition in Hepatocellular Carcinoma
van Zijl, F., Zulehner, G., Petz, M., Schneller, D., Kornauth, C., Hau, M., Machat, G., Grubinger, M., Huber, H., & Mikulits, W. (2009) · Future Oncology · doi:10.2217/fon.09.91 · Cited by 320
Hui, L., Zatloukal, K., Scheuch, H., Stępniak-Konieczna, E., & Wagner, E. F. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37156 · Cited by 313
Cardenes, H. R., Price, T. R., Perkins, S. M., Maluccio, M. A., Kwo, P. Y., Breen, T., Henderson, M. A., Schefter, T. E., Tudor, K., Deluca, J., et al. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0492-x · Cited by 307
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2791 · Cited by 307
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 316
Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306
Self-citationChung, G. E., Lee, J., Kim, H. Y., Hwang, S. Y., Kim, J. S., Chung, J. W., Yoon, J., Lee, H.-S., & Kim, Y. J. (2011) · Radiology · doi:10.1148/radiol.10101058 · Cited by 305
Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
Olejarz, W., Kubiak-Tomaszewska, G., Chrzanowska, A., & Lorenc, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165840 · Cited by 299
Mir, O., Coriat, R., Blanchet, B., Durand, J.-P., Boudou, P., Michels, J., Ropert, S., Vidal, M., Pol, S., Chaussade, S., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037563 · Cited by 304
Novel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 310
Pawlik, T. M., Reyes, D. K., Cosgrove, D., Kamel, I. R., Bhagat, N., & Geschwind, J.-F. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.1021 · Cited by 304
Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
Daher, S., Massarwa, M., Benson, A. A., & Khoury, T. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00031 · Cited by 309
Kudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., Aikata, H., Nagano, H., Hatano, E., Sasaki, Y., et al. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30078-5 · Cited by 304
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 315
Fojo, T., Mailankody, S., & Lo, A. W. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 309
MicroRNA involvement in hepatocellular carcinoma
Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00533.x · Cited by 305
Self-citationPrecision diagnosis and treatment of liver cancer in China
Fu, J., & Wang, H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.008 · Cited by 302
Recent progress in treatment of hepatocellular carcinoma.
Chen, Z., Xie, H., Hu, M., Huang, T., Hu, Y., Sang, N., & Zhao, Y. (2020) · PubMed Central · Cited by 299
Role of nonresolving inflammation in hepatocellular carcinoma development and progression
Yu, L., Yan, L., & Wang, H. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0048-z · Cited by 309
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer
Bao, M. H.-R., & Wong, C. C.-L. (2021) · Cells · doi:10.3390/cells10071715 · Cited by 316
Hasegawa, K., Takemura, N., Yamashita, T., Watadani, T., Kaibori, M., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Aikata, H., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13892 · Cited by 300
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
Xia, S., Pan, Y., Liang, Y., Xu, J., & Cai, X. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2019.102610 · Cited by 299
Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316408 · Cited by 326
Self-citationIntratumor Heterogeneity in Hepatocellular Carcinoma
Friemel, J., Rechsteiner, M., Frick, L. D., Böhm, F., Struckmann, K., Egger, M., Moch, H., Heikenwälder, M. F., & Weber, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0122 · Cited by 297
Liver transplantation: past, present and future
Zarrinpar, A., & Busuttil, R. W. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.88 · Cited by 299
Zhu, H., Li, H.-L., Huang, M., Yang, W.-Z., Yin, G., Zhong, B., Sun, J., Jin, Z., Chen, J.-J., Ge, N., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01235-0 · Cited by 300
Cancer and liver cirrhosis: implications on prognosis and management
Pinter, M., Trauner, M. A., Peck‐Radosavljevic, M., & Sieghart, W. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000042 · Cited by 295
Mejías, M., García‐Pras, E., Tiani, C., Miquel, R., Bosch, J., & Fernández, M. (2008) · Hepatology · doi:10.1002/hep.22758 · Cited by 299
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Greten, T. F., Lai, C. W., Li, G., & Staveley-O’Carroll, K. F. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.051 · Cited by 297
Self-citationThe yin and yang of evasion and immune activation in HCC
Makarova‐Rusher, O. V., Medina‐Echeverz, J., Duffy, A. G., & Greten, T. F. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.038 · Cited by 299
Self-citationAlpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma
Sauzay, C., Petit, A., Bourgeois, A.-M., Barbare, J., Chauffert, B., Galmiche, A., & Houessinon, A. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.10.006 · Cited by 293
Bollard, J., Miguela, V., de Galarreta, M. R., Venkatesh, A., Bian, C. B., Roberto, M. P., Tovar, V., Sia, D., Molina-Sánchez, P., Nguyen, C. B., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-312268 · Cited by 291
Self-citationCardiovascular Complications of Cancer Therapy
Chang, H., Okwuosa, T. M., Scarabelli, T. M., Moudgil, R., & Yeh, E. T. H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1095 · Cited by 296
The impact of VEGF on cancer metastasis and systemic disease
Yang, Y., & Cao, Y. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.011 · Cited by 309
Faivre, S. J., Raymond, É., Boucher, É., Douillard, J.-Y., Lim, H. Y., Kim, J. S., Zappa, M., Lanzalone, S., Lin, X., DePrimo, S. E., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70171-8 · Cited by 290
Liang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., Liu, H., Tian, L., Fang, X., Meng, X., et al. (2013) · Hepatology · doi:10.1002/hep.26224 · Cited by 289
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Chan, S. L., Dawson, L. A., Kelley, R. K., Llovet, J. M., Meyer, T., Ricke, J., Rimassa, L., Sapisochín, G., Vilgrain, V., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.006 · Cited by 338
Self-citationXu, J., Wan, Z., Tang, M., Lin, Z., Shi, J., Ji, L., Gorshkov, K., Mao, Q., Xia, S., Cen, D., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01281-8 · Cited by 293
Zhai, B., Hu, F., Jiang, X. L., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1043 · Cited by 286
Liver cancer: Approaching a personalized care
Bruix, J., Han, K., Gores, G. J., Llovet, J. M., & Mazzaferro, V. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.007 · Cited by 290
Self-citationDhir, M., Melin, A. A., Douaiher, J., Lin, C. H., Zhen, W. K., Hussain, S. M., Geschwind, J.-F. H., Doyle, M. B. M., Abou‐Alfa, G. K., & Are, C. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001556 · Cited by 285
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500394m · Cited by 285
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M. S., Lenz, H., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P. C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0927-7 · Cited by 284
Angiogenesis in pancreatic cancer: current research status and clinical implications
Li, S., Xu, H., Wu, C., Wang, W.-Q., Jin, W., Gao, H.-L., Li, H., Zhang, S.-R., Xu, J.-Z., Qi, Z.-H., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9645-2 · Cited by 287
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 292
Major achievements in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60381-0 · Cited by 287
Self-citationIn vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente‐Macías, Á., Baillache, D. J., Croke, S., & Unciti‐Broceta, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 294
Takahashi, K., Yan, I. K., Wood, J., Haga, H., & Patel, T. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0636 · Cited by 258
Lyu, N., Kong, Y., Mu, L., Lin, Y., Li, J., Liu, Y., Zhang, Z., Zheng, L., Deng, H., Li, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.008 · Cited by 281
Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M., & Omata, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061358 · Cited by 289
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
Foerster, F., Gairing, S. J., Müller, L., & Galle, P. R. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.007 · Cited by 285
Self-citationGarin, É., Lenoir, L., Rolland, Y., Edeline, J., Mesbah, H., Laffont, S., Porée, P., Clément, B., Raoul, J., & Boucher, E. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094235 · Cited by 280
Self-citation
Metadata
- Authors
- Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J.-F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., & Bruix, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- University of Pisa (IT)
- Auckland City Hospital (NZ)
- Cliniques Universitaires Saint-Luc (BE)
- Université Européenne de Bretagne (FR)
- Centro de Investigación Biomédica en Red (ES)
- Goethe University Frankfurt (DE)
- Medizinische Hochschule Hannover (DE)
- Johannes Gutenberg University Mainz (DE)
- Aix-Marseille Université (FR)
- Bayer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-24
- Volume
- 359
- Issue
- 4
- Pages
- 378-390
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1971837077
- Cited by
- 13,097
- References
- 66
- Citations by year
- 2026: 390 · 2025: 623 · 2024: 729 · 2023: 874 · 2022: 1003 · 2021: 1093 · 2020: 971 · 2019: 816 · 2018: 746 · 2017: 814 · 2016: 704 · 2015: 730 · 2014: 753 · 2013: 695 · 2012: 624
- FWCI
- 369.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Falk Foundation
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Bayer HealthCare
- Eisai
- Merz Pharmaceuticals
- Ipsen
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- sorafenib, hepatocellular carcinoma, multikinase inhibitor, VEGFR, PDGFR, Raf, overall survival, adverse effects, hand-foot skin reaction, hypophosphatemia, diarrhea, weight loss
- MeSH terms
- Sorafenib, Aged, Benzenesulfonates, Double-Blind Method, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Niacinamide, Phenylurea Compounds, Pyridines, Proportional Hazards Models, Survival Analysis, Chemotherapy, Adjuvant, Disease Progression, Protein Kinase Inhibitors, raf Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
